Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroendocrine Tumors 3Paraganglioma 2Neuroblastoma 2Carcinoid Tumor 2Tumor Positron-Emission Tomography 1Pheochromocytoma 1Meningioma 1Medulloblastoma 1

Interventions

lutetium Lu 177 dotatate 2Specimen Handling 2Magnetic Resonance Spectroscopy 2pembrolizumab 1olaparib 1gallium Ga 68 dotatate 1fludarabine 1Surgical Procedures, Operative 1Semaxinib 1Radiosurgery 1Proton Therapy 1Nivolumab 1Lysine 1Ipilimumab 1Interleukin-2 1Imatinib Mesylate 1Ga(III)-DOTATOC 1Erlotinib Hydrochloride 1Cyclophosphamide 1Crossing Over, Genetic 1CTLA-4 Antigen 1Arginine 164Cu-SARTATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1177Lu-DOTA-JR11 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Meningioma × gallium Ga 68 dotatate × Clear all
NCT07150806 2026-05-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡